Cargando…

Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant

BACKGROUND: Cytomegalovirus (CMV) infection is a common opportunistic infection after allogeneic hematopoietic cell transplant (alloHCT). We explored whether a change in CMV cell-mediated immunity during the first month after transplant predicts the risk of development of CMV infection and all-cause...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ariza-Heredia, Ella J, Winston, Drew J, Rowley, Scott D, Mullane, Kathleen, Chandrasekar, Pranatharthi, Hari, Parameswaran, Avery, Robin K, Peggs, Karl S, Kumar, Deepali, Nath, Rajneesh, Ljungman, Per, Mossad, Sherif B, El Haddad, Lynn, Shah, Dimpy P, Jiang, Ying, Khawaja, Fareed, Dadwal, Sanjeet, Blanchard, Ted, Chemaly, Roy F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460252/ https://www.ncbi.nlm.nih.gov/pubmed/37636519 http://dx.doi.org/10.1093/ofid/ofad386

Ejemplares similares

940. The use of a commercially available CMV T Cell Immunity Panel to Assess the Risk of CMV Infections in Hematopoietic Cell Transplant Recipients with Low Level CMV Viremia
por: Khawaja, Fareed, et al.
Publicado: (2021)

2121. The Impact of Donor CMV Serostatus on Outcomes of CMV Infections in the Era of Letermovir
por: Aramburo, Oscar Morado, et al.
Publicado: (2022)

The Immunology of Posttransplant CMV Infection: Potential Effect of CMV Immunoglobulins on Distinct Components of the Immune Response to CMV
por: Carbone, Javier
Publicado: (2016)

568. Healthcare Cost and Length of Stay for Cytomegalovirus (CMV) Infection-Related Hospitalizations in Allogeneic Hematopoietic Cell Transplant (allo-HCT) recipients: A Multicenter Analysis
por: Khawaja, Fareed, et al.
Publicado: (2020)

922. The Impact of Clinically Significant CMV Infections on Other Viral Infections in the Era of Letermovir Primary Prophylaxis
por: Spallone, Amy, et al.
Publicado: (2021)

580. Refractory and Resistant CMV Infections in Hematopoietic Cell Transplant Recipients in the Letermovir Primary Prophylaxis Era
por: Sassine, Joseph, et al.
Publicado: (2020)

1538. High Mortality of Cytomegalovirus (CMV) Pneumonia in Hematopietic Cell Transplant Recipients
por: Batista, Marjorie, et al.
Publicado: (2018)

Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation
por: Lodding, I P, et al.
Publicado: (2018)

2122. The Impact of HHV-6 DNAemia on hematopoietic cell transplant (HCT) recipients at high risk for CMV reactivation in the era of Letermovir
por: Srinivasan, Krithia, et al.
Publicado: (2022)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

1561. Outcomes of Resistant or Refractory CMV Infection in Recipients of Allogeneic Hematopoietic Cell Transplant
por: Artau, Annette, et al.
Publicado: (2018)

Correlation of Cytomegalovirus (CMV) Disease Severity and Mortality With CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative Solid Organ Transplant Recipients
por: McBride, Jacqueline M, et al.
Publicado: (2019)

Whole CMV Proteome Pattern Recognition Analysis after HSCT Identifies Unique Epitope Targets Associated with the CMV Status
por: Pérez-Bercoff, Lena, et al.
Publicado: (2014)

CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients
por: Schulz, Uwe, et al.
Publicado: (2016)

Predictors of CMV Infection in CMV-Seropositive Kidney Transplant Recipients: Impact of Pretransplant CMV-Specific Humoral Immunity
por: Kirisri, Similan, et al.
Publicado: (2021)

1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients
por: Marty, Francisco M, et al.
Publicado: (2018)

Association of CMV-Specific T Cell-Mediated Immunity with CMV DNAemia and Development of CMV Disease in HIV-1–Infected Individuals
por: Aichelburg, Maximilian C., et al.
Publicado: (2015)

Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors
por: He, Ran, et al.
Publicado: (2011)

Stimulatory Effect of CMV Immunoglobulin on Innate Immunity and on the Immunogenicity of CMV Antigens
por: Deml, Ludwig, et al.
Publicado: (2021)

CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis
por: Goodman, A. L., et al.
Publicado: (2014)

604 Risk Factors for Cytomegalovirus (CMV) Reactivation in CMV-seropositive Liver Transplant Patients
por: Bruminhent, Jackrapong, et al.
Publicado: (2014)

RhCMV serostatus and vaccine adjuvant impact immunogenicity of RhCMV/SIV vaccines
por: Chang, W. L. William, et al.
Publicado: (2020)

Association of CMV genomic mutations with symptomatic infection and hearing loss in congenital CMV infection
por: Dobbins, G. Clement, et al.
Publicado: (2019)

THE PREVALENCE OF CYTOMEGALOVIRUS (CMV) VIRURIA AMONG HOSPITALIZED CHILDREN AND THE RISK OF CMV ACQUISITION BY NURSES
por: Adler, Stuart P, et al.
Publicado: (1984)

cmv1-Mediated Resistance to CMV in Melon Can Be Overcome by Mixed Infections with Potyviruses
por: Giordano, Andrea, et al.
Publicado: (2023)

Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR T cells with CMV vaccine
por: Guan, Min, et al.
Publicado: (2022)

Lack of cytomegalovirus (CMV)-specific cell-mediated immune response using QuantiFERON-CMV assay in CMV-seropositive healthy volunteers: fact not artifact
por: Valle-Arroyo, Jorge, et al.
Publicado: (2020)

1198. Measurement of Pre-transplant Anti-cytomegalovirus (CMV) Immunoglobulin G Titer to Predict Risk of CMV Infection in CMV-seropositive Kidney Transplant Recipients
por: Kirisri, Similan, et al.
Publicado: (2020)

Cytomegalovirus (CMV)-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation
por: Wang, Xiaodong, et al.
Publicado: (2021)

Successful Use of Heterologous CMV-Reactive T Lymphocyte to Treat Severe Refractory Cytomegalovirus (CMV) Infection in a Liver Transplanted Patient: Correlation of the Host Antiviral Immune Reconstitution with CMV Viral Load and CMV miRNome
por: Miele, Monica, et al.
Publicado: (2021)

γδ T cells take on CMV
por: Van Epps, Heather L.
Publicado: (2005)

CMV Oophoritis in an AIDS Patient
por: Albert, Michael S., et al.
Publicado: (1995)

CMV and Triggers of Systemic Sclerosis
Publicado: (2006)

CMV Pancreatitis in an Immunocompromised Patient
por: Ahmad, Jaffer, et al.
Publicado: (2021)

Cytomegalovirus (CMV) Infection and Latency
por: O’Connor, Christine M.
Publicado: (2021)

Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: Impact of CMV infection and leukemia relapse
por: Luo, Xiao-Hua, et al.
Publicado: (2023)

Effect of ageing on CMV-specific CD8 T cells from CMV seropositive healthy donors
por: Pita-Lopez, María Luisa, et al.
Publicado: (2009)

CMV Serostatus of Donor-Recipient Pairs Influences the Risk of CMV Infection/Reactivation in HSCT Patients
por: Jaskula, Emilia, et al.
Publicado: (2012)

Impact of CMV Infection on Natural Killer Cell Clonal Repertoire in CMV-Naïve Rhesus Macaques
por: Truitt, Lauren L., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0bjl850fgvuo60229knr3pq77t